The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.
A Great Stock for a Lousy Market
by Alexander Green, Oxford Club Investment Director
In our Oxford Club 2009 January Forecast issue, we agreed with the consensus that the economy will be an unmitigated disaster this year, but noted that the stock market might surprise investors on the upside, especially in the second half.
This is all well and good, one member wrote recently, but what about the first half? Should we hang out in cash until the coast is clear?
Absolutely not. Investors who are fully in cash have chosen a terrible long-term asset, one with a negative real yield.
Buy when times are good and sell when things look bad and you’re virtually guaranteed to buy high and sell low. Plus, you’re likely to miss some of the best days in the market.
This matters more than you might realize.
Javier Estrada, a finance professor at IESE Business School, has studied the daily returns of the Dow Jones Industrial Average back to 1900. He found that if you took away the 10 best days, two-thirds of the cumulative gains produced by the Dow over the past 109 years would disappear. (Two-thirds!)
Only 10 days out of 29,694 made all the difference. What are your chances of predicting those days in advance?
Virtually nil.
So rather than trying to outguess the market, let’s focus for now on companies that are likely to post surprisingly good earnings despite the downturn…
To continue reading and get all the Oxford Club’s latest updates, subscribe today
- Momentum Investing: A Proven Investment Strategy That Earns 350% When Put to the Test
- Stock Market Investment Advice: Beware Wall Street’s “Tower of Babble”
- The Best Stock Market Buy Signal In 51 Years
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed